Azienda Sanitaria Locale Napoli 2 Nord

At Azienda Sanitaria Locale Napoli 2 Nord, the clinical trial portfolio is centered on oncology, with a strong focus on cancers of the urinary tract, prostate, breast, and kidney. The studies are mainly designed to test new treatment options, compare them with current standards of care, and improve outcomes for people with advanced or high-risk cancers.

• Research in urothelial carcinoma and bladder cancer, including approaches for locally advanced, metastatic, and non-muscle invasive disease
• Studies in prostate cancer, especially metastatic castration-sensitive and metastatic castration-resistant forms
• Trials in breast cancer focused on early, node-positive, hormone receptor-positive disease with higher recurrence risk
• Investigations in renal cell carcinoma for patients with oligometastatic, locally advanced, or metastatic disease

The site’s research is aimed at evaluating whether newer targeted therapies, immunotherapy-based combinations, and other treatment strategies can better control tumor growth and extend survival across several solid tumors.

A major part of the research activity at this hospital involves urothelial cancer, including advanced urothelial carcinoma, muscle-invasive bladder cancer, and non-muscle invasive bladder cancer. These trials are exploring whether new drug combinations or bladder-preserving strategies can improve disease control and help patients avoid progression.

• Comparing new HER2-targeted and immunotherapy combinations with standard chemotherapy for advanced disease
• Assessing bladder-preserving treatment options for muscle-invasive bladder cancer
• Evaluating a new therapy for non-muscle invasive bladder cancer to improve local disease management
• Studying whether tumor biomarkers can help predict response to platinum-based chemotherapy

This research aims to refine treatment selection and improve outcomes for patients with bladder and urothelial tumors.

The site also conducts trials in prostate cancer, with attention to both metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer. These studies are focused on whether adding newer targeted agents or immune-based treatments can improve disease control compared with established hormonal or chemotherapy approaches.

• Testing new combinations for HRR gene-mutated metastatic castration-sensitive prostate cancer
• Evaluating treatment strategies for metastatic castration-resistant prostate cancer
• Exploring whether novel therapies can delay progression and improve radiographic progression-free survival
• Comparing emerging options with current standard of care in advanced disease

Overall, the studies aim to improve long-term control of advanced prostate cancer and identify more effective treatment pathways for patients with limited options.

Research at Azienda Sanitaria Locale Napoli 2 Nord extends beyond urologic cancers to include early breast cancer and renal cell carcinoma. In breast cancer, the focus is on reducing recurrence risk, while kidney cancer studies are examining how to better control metastatic disease and support surgical or local treatment strategies.

• Studying early breast cancer with high risk of recurrence to see if a new endocrine treatment improves long-term outcomes
• Investigating oligometastatic renal cell carcinoma to determine whether treatment can delay tumor progression before or around surgery and radiotherapy
• Evaluating whether immunotherapy and local tumor treatment can improve survival in metastatic renal cell carcinoma
• Comparing new approaches with established therapies to improve disease-free survival and overall disease control

These trials reflect a broader effort to improve care for patients with solid tumors by testing more effective and better-targeted treatment approaches.